NOVEMBER SALE - 20% OFF Everything!Shop Now
BPC-157 and TB-500 Capsules

BPC-157 and TB-500 Capsules

$86.00each

4.7· 3 reviewsout of 5In stock

Buy BPC-157 and TB-500 capsules, 250 mcg of each peptide per capsule, for oral-route animal research. Independent lab tested. Ships within 24 hours from the US.

Regular price $108.00Sale price $86.00You save $22.00 (20%)
1

Bundle & Save

Need more?

Select and SubscribeSave 20%
Order within 1h 17m to ship Fri, Nov 20Cutoff 5:00 PM PST · ships next business day
U.S. delivery availableFree shipping on orders over $150.00
Reship policyWrong item sent? We reship it free. Transit issues reviewed case by case.

Secure checkout · Visa · Mastercard · American Express · Discover · PayPal · Venmo · Apple Pay

Product details

BPC-157 and TB-500 capsules, in brief. Repairing an injury takes several steps: blood vessels have to grow back into the damaged area, and repair cells have to move in and rebuild it. BPC-157 and TB-500 are two unrelated peptides that have each been studied for one of those steps. BPC-157 is linked mainly to new blood vessel growth, and TB-500, derived from the actin-binding protein thymosin beta-4, mainly to cell movement. In one rat study of repaired Achilles tendons, TB-500 given alone by injection made the tendon significantly stronger and BPC-157 alone added collagen, but the two together did no better than either one [1]. These capsules put both peptides in an oral format, and the oral evidence for the two is very different. BPC-157 stays intact in gastric juice for more than a day, and rats given it in drinking water healed several gut and bladder injuries [2,3]. For TB-500, no study was found that gave it by mouth, so whether it survives digestion and reaches tissue intact is unknown. NextGenPeps supplies BPC-157 and TB-500 capsules, listed at 250 mcg of each peptide per capsule, for laboratory use only.

What do BPC-157 and TB-500 do?

In animal and cell studies, each peptide speeds a different part of tissue repair. BPC-157 work centres on blood vessels growing back into an injury, and thymosin beta-4 work centres on repair cells moving in [4,5].

In animal studies that has meant three things:

  • Tendon. In rats with a surgically repaired Achilles tendon, the TB-500 group had the strongest tendons at four weeks, and the BPC-157 group laid down more type I collagen than controls [1].

  • Fistulas and gut injuries, by mouth. BPC-157 given in drinking water closed surgically made fistulas in rats, including fistulas between the bladder and vagina and between gut and skin [2,3].

  • Blood vessels and cell movement. BPC-157 raised the vessel growth receptor VEGFR2 in endothelial cells and sped blood-flow recovery in rat hind-limb ischemia [4]; thymosin beta-4 drives cell migration and new vessel growth [5].

What the pair adds over its parts is not established, and the only combination study found no added benefit [1].

NextGenPeps supplies BPC-157 and TB-500 capsules for in vitro research and approved animal studies only. They are not sold as a drug, supplement or diagnostic.

How do BPC-157 and TB-500 work?

They act on different parts of the repair process: BPC-157 on blood vessel growth signalling, TB-500 on the actin machinery that lets cells move.

BPC-157. In cultured endothelial cells BPC-157 raised levels of VEGFR2, the main receptor for the vessel growth factor VEGF, and switched on the VEGFR2, Akt and eNOS chain that produces nitric oxide [4]. In fibroblasts from rat Achilles tendon it did not speed cell division but increased outgrowth, survival under oxidative stress and migration through the FAK and paxillin adhesion pathway [6].

TB-500. Thymosin beta-4 is the main protein that binds and stores single actin units inside cells, the building blocks of the filaments a cell uses to change shape and crawl. Outside cells it has been linked to cell migration, new vessel growth and lower inflammation in injured tissue [5]. The actin-binding work is done by a seven-residue stretch, LKKTETQ, which matched the full protein in endothelial migration and vessel sprouting assays [7]. That stretch, N-acetylated, is the TB-500 listed for these capsules.

What did BPC-157 and TB-500 do in animal studies?

Rat tendons healed stronger, and rat fistulas closed. The tendon result comes from injected peptides; the fistula results come from BPC-157 given by mouth.

Both peptides, injected, in rat tendons. In a 2026 study, rats had the Achilles tendon cut and surgically repaired, then received daily intraperitoneal vehicle, BPC-157, TB-500 described as a synthetic peptide derived from thymosin beta-4, or both, for four weeks (8 rats per group). Median load to failure was 26.9 N in controls, 37.2 N with BPC-157, 37.4 N with TB-500 and 34.5 N with both (Figure 1). Only TB-500 differed significantly from control (P=0.04). Under the microscope, TB-500 gave the best tendon healing scores, BPC-157 increased type I collagen (P=0.009), and the combination improved one healing score (P=0.04) without beating either peptide alone. Mechanical testing used only four tendons per group [1].

Bar chart of rat Achilles tendon load to failure four weeks after repair: control 26.9 newtons, BPC-157 37.2, TB-500 37.4 (P=0.04 versus control), and BPC-157 plus TB-500 34.5, with peptides given by daily intraperitoneal injection.

Figure 1. Rat Achilles tendon strength four weeks after repair. Median load to failure, four tendons tested per group; peptides were injected, not given by mouth. Source: Biçer et al., Jt Dis Relat Surg 2026.[1]

BPC-157 by mouth, in rat fistulas. In a 2021 study, female rats had a 4 mm fistula made between the bladder and vagina, and two weeks later received BPC-157 daily in drinking water or by intraperitoneal injection, with 6 rats per group at each time point up to six weeks. With both routes, urine stopped leaking through the vagina within the first week of therapy in every treated rat, while controls kept leaking. By the fourth week the treated bladders held five times more fluid before leaking than control bladders, matching healthy rats. Both the bladder and vaginal defects closed in treated rats, and none formed bladder stones, against stones in all controls at the later time points [3]. A review from the same research group reports similar closure of gut-to-skin, colon-to-bladder and rectum-to-vagina fistulas in rats given BPC-157 in drinking water [2]. Most of the oral BPC-157 work comes from that one group.

Does oral TB-500 work?

It has not been shown. No published study was found that gave TB-500, in either form, to animals by mouth, so oral activity is untested rather than disproven.

The two peptides in these capsules differ sharply in what is known about the oral route (Figure 2):

  • BPC-157. It is described as native and stable in gastric juice for more than 24 hours in vitro, which is unusual for a peptide, and it has healed injuries in rats when given in drinking water [2,3]. Its oral absorption has still not been measured: the pharmacokinetic work in rats and dogs used intravenous and intramuscular dosing only, and found a half-life under 30 minutes [8].

  • Full-length thymosin beta-4. A 43-residue protein of about 5 kDa. Proteins of this size generally face the digestive enzymes and the barrier of the gut wall that keep most peptides and proteins from being absorbed intact by mouth [9]. No oral stability, absorption or efficacy data for it were found.

  • The LKKTETQ fragment. At seven residues and 889 g/mol it is far smaller, but no oral stability, absorption or efficacy data for it were found either. Its activity has been shown in cell and tissue assays [7].

Evidence grid for the oral route: BPC-157 is stable in gastric juice for over 24 hours and healed injuries in rats given drinking water, while for TB-500 no gastric stability or oral study was found; oral absorption has not been measured for either, both healed rat injuries when injected, and the pair has not been studied together by mouth.

Figure 2. What is known about the oral route. Published evidence for each capsule component; "no study found" means none was located for this page. Sources: Seiwerth et al. 2021, Rasic et al. 2021, He et al. 2022, Biçer et al. 2026.[1,2,3,8]

The oral BPC-157 studies dissolved the peptide in drinking water. None used a capsule, and no study has given BPC-157 and TB-500 together by mouth.

BPC-157 and TB-500 capsules vs the vial blend

Same two peptide names, different format, different evidence base.

  • Route studied. The only combination study injected both peptides [1]. Oral data exist for BPC-157 alone [2,3].

  • Format. The capsules hold a fixed 250 mcg of each peptide per capsule for oral-route work. The vial blend is lyophilized powder reconstituted for injected-route models.

  • TB-500 form. The capsules are listed with the Ac-LKKTETQ fragment, while the NextGenPeps TB-500 vial contains full-length thymosin beta-4. Results from one form should not be assumed for the other.

Related research formats: BPC-157 Capsules for oral-route work on BPC-157 alone, and the BPC-157 / TB-500 vial blend.

What are BPC-157 and TB-500 capsules made of?

Two synthetic peptides in each capsule, listed at equal mass. Because the two molecules differ in size, equal mass does not mean equal numbers of molecules.

BPC-157 is a linear peptide of 15 amino acids, GEPPPGKPADDAGLV, formula C62H98N16O22, 1419.5 g/mol (CAS 137525-51-0), a partial sequence of a protein described in gastric juice.

TB-500 in these capsules is listed as the N-acetylated seven-residue fragment Ac-LKKTETQ, residues 17 to 23 of thymosin beta-4, formula C38H68N10O14, 889.0 g/mol. Full-length thymosin beta-4 is 43 residues and 4963.5 g/mol.

At 250 mcg each, one capsule holds about 176 nmol of BPC-157 and about 281 nmol of the TB-500 fragment, roughly 1.6 fragment molecules per BPC-157 molecule (Figure 3). If a lot contained full-length thymosin beta-4 instead, the same mass would be only about 50 nmol.

Bar chart of molecules per capsule: 176 nanomoles of BPC-157, 281 nanomoles of TB-500 as the Ac-LKKTETQ fragment, and 50 nanomoles if the TB-500 were full-length thymosin beta-4, each from 250 micrograms.

Figure 3. One capsule: equal mass, unequal molecule counts. Calculated from 250 mcg per peptide and average molecular weight. Which TB-500 form a lot contains should be confirmed by mass on its certificate of analysis.

BPC-157 and TB-500 capsules at a glance

  • Compound: BPC-157 plus TB-500 (Ac-LKKTETQ, thymosin beta-4 fragment 17 to 23), in one capsule

  • Class: Two-peptide research combination: synthetic pentadecapeptide plus synthetic actin-binding heptapeptide

  • BPC-157: GEPPPGKPADDAGLV; C62H98N16O22; 1419.5 g/mol; CAS 137525-51-0

  • TB-500: Ac-LKKTETQ; C38H68N10O14; 889.0 g/mol

  • Strength: 250 mcg BPC-157 and 250 mcg TB-500 per capsule, as listed

  • Identity and purity: Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library

  • Appearance: Capsules in a sealed container

  • Reconstitution: Not required

  • Half-life: BPC-157 under 30 minutes in rats and dogs after intravenous or intramuscular dosing [8]; no oral or fragment data found

  • Regulatory status: Neither peptide is an FDA-approved drug. Both prohibited in sport by the World Anti-Doping Agency [10]

Are BPC-157 and TB-500 legal or FDA approved?

Neither is an FDA-approved drug, and these capsules are sold only as research material.

On April 15, 2026, the FDA removed twelve peptides, including BPC-157 and the thymosin beta-4 fragment LKKTETQ ("TB-500"), from Category 2 of its interim list of bulk substances that raise significant safety concerns for pharmacy compounding. Removal did not by itself make them eligible for compounding [11]. At its July 23, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157, KPV and TB-500; the vote is not binding and the FDA must still complete rulemaking [12].

In sport, the World Anti-Doping Agency lists BPC-157 as a non-approved substance (S0) and thymosin beta-4 and its derivatives, such as TB-500, as prohibited growth factor modulators (S2) [10].

What are BPC-157 and TB-500 capsules used to study?

Mainly the oral route itself: whether these peptides act, and survive, when given by mouth in animal models.

  • Oral peptide stability. Gastric and intestinal stability of BPC-157 next to a short actin-binding peptide, in vitro [2,9].

  • Oral-route animal models. Gut, fistula and bladder injury models where oral BPC-157 has been tested, and whether adding TB-500 changes the result [2,3].

  • Tendon healing. Comparison with the injected combination results in repaired rat Achilles tendon [1].

  • Exposure measurement. Oral absorption has not been measured for BPC-157 [8] or TB-500, which is the open question for any oral protocol.

Buying BPC-157 and TB-500 capsules for research: what each container includes

For a two-peptide product, identity matters as much as purity, because two different molecules share the name TB-500. Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library.

  • Fixed composition. 250 mcg BPC-157 and 250 mcg TB-500 per capsule, as listed.

  • Independent testing. Identity and purity are tested by independent labs, with the certificate published in the COA library.

  • US-based fulfilment. Orders ship within 24 hours from the United States, with free US shipping on orders over $150.

  • Research use only. BPC-157 and TB-500 capsules are sold strictly for in vitro and approved animal research. They are not for human or veterinary use and are not sold as a drug, supplement or diagnostic.

BPC-157 and TB-500 capsules handling, storage and analytical notes

Format. Supplied as capsules in a sealed container; no reconstitution is needed. No dosing instructions are supplied, and none should be taken from the studies above.

Storage. The product record lists storage at 2 to 8 °C. Keep the container sealed, dry and protected from light, and limit time open to room air, since moisture degrades peptides.

Identity check. Mass spectrometry should show BPC-157 near 1419 Da and the TB-500 fragment near 889 Da. A mass near 4963 Da would indicate full-length thymosin beta-4 instead.

Oral-route design. Because oral absorption of BPC-157 is unmeasured [8] and no oral data exist for TB-500, oral studies need their own exposure measurements rather than assuming values from injected work.

Naming. TB-500 is used for both full-length thymosin beta-4 and the LKKTETQ fragment; Ac-LKKTETQ and thymosin beta-4 fragment 17-23 refer to the fragment. BPC-157 is also written BPC 157 or pentadecapeptide BPC 157.

What is not established about BPC-157 and TB-500 capsules

  • Oral TB-500. No study was found that gave either form of TB-500 by mouth, so its oral stability, absorption and activity are unknown.

  • Oral absorption of BPC-157. Oral BPC-157 healed rat injuries, but how much reaches the bloodstream has not been measured [8].

  • The combination by mouth. The only combination study injected both peptides, and even there the pair did not beat either peptide alone [1].

  • Capsule versus drinking water. The oral BPC-157 studies used drinking water. No study has tested a capsule format, and the oral data come mostly from a single research group [2,3].


Research Use Only. The statements made within this website have not been evaluated by the US Food and Drug Administration. These materials are not intended to diagnose, treat, cure or prevent any disease and are not intended for human or veterinary use. Studies described on this page are reported for scientific context and are not guidance of any kind.

Published research

Compound information

Molecular class
Two-peptide research combination: synthetic pentadecapeptide (BPC-157) plus synthetic thymosin beta-4 fragment (TB-500)
BPC-157
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV); C₆₂H₉₈N₁₆O₂₂; 1419.5 g/mol; CAS 137525-51-0
TB-500
Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), thymosin beta-4 residues 17 to 23, N-acetylated; C₃₈H₆₈N₁₀O₁₄; 889.0 g/mol
Strength
250 mcg BPC-157 and 250 mcg TB-500 per capsule, as listed
Molecules per capsule
BPC-157 about 176 nmol; TB-500 fragment about 281 nmol (calculated)
Physical form
Capsules in a sealed container
Purity
Every lot is tested by independent labs; certificate of analysis published in the NextGenPeps COA library
Oral data
BPC-157: rat drinking-water studies; TB-500: no oral study found
Regulatory status
Research use only. Neither peptide is FDA-approved; both prohibited by WADA (S0 and S2)

Storage & stability

  • Capsules in a sealed container
  • Store cold, dry and protected from light
  • Limit time open to room air; moisture degrades peptides
  • No reconstitution required
Sealed container
2 to 8 °C, as listed on the product record
After opening
Reseal promptly; keep dry and cold, protected from light
Identity check
BPC-157 near 1419 Da; TB-500 fragment near 889 Da (a mass near 4963 Da indicates full-length thymosin beta-4)

Cited literature

  1. 01
    Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

    Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY · Jt Dis Relat Surg 2026 · DOI · Free full text

    Rats with repaired Achilles tendons (n=8 per group) received daily intraperitoneal vehicle, BPC-157, TB-500 or both for four weeks. Load to failure: 26.9, 37.2, 37.4 and 34.5 N; only TB-500 was significant, and the pair did not beat either alone. Injected, not oral; four tendons per group for mechanics; TB-500 form not specified.

  2. 02
    Stable gastric pentadecapeptide BPC 157 and wound healing

    Seiwerth S, Milavic M, Vukojevic J, et al. · Front Pharmacol 2021 · PubMed · DOI · Free full text

    Review describing BPC 157 as stable in gastric juice for more than 24 hours and healing several rat fistula models when given in drinking water. Results are qualitative and come from the authors' own group; oral bioavailability is not reported.

  3. 03
    Stable gastric pentadecapeptide BPC 157 heals established vesicovaginal fistula and counteracts stone formation in rats

    Rasic D, Zenko Sever A, Rasic F, et al. · Biomedicines 2021 · PubMed · DOI · Free full text

    BPC 157 in drinking water or by injection stopped vaginal urine leakage within a week, raised bladder capacity fivefold by week four, closed both defects and prevented stones in rats (6 per group per time point). Small groups; routes are reported together.

  4. 04
    Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation

    Hsieh MJ, Liu HT, Wang CN, et al. · J Mol Med 2017 · PubMed · DOI

    BPC 157 raised VEGFR2 (not VEGF-A), drove VEGFR2 internalisation and Akt-eNOS signalling, and sped blood-flow recovery in rat hind-limb ischemia. The abstract gives no effect sizes.

  5. 05
    Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues

    Goldstein AL, Hannappel E, Kleinman HK · Trends Mol Med 2005 · PubMed · DOI

    Review describing thymosin beta-4 as the major actin-sequestering molecule in cells, with roles in cell migration, angiogenesis and wound repair. A narrative review by researchers active in the field.

  6. 06
    The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

    Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH · J Appl Physiol 2011 · PubMed · DOI

    In rat tendon fibroblasts, BPC 157 increased explant outgrowth, survival under oxidative stress and migration via FAK-paxillin, without changing proliferation. In vitro only.

  7. 07
    The actin binding site on thymosin beta4 promotes angiogenesis

    Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK · FASEB J 2003 · DOI

    The seven-residue actin-binding motif matched full-length thymosin beta-4 in endothelial migration and vessel sprouting assays at about 50 nM; peptides lacking part of it were inactive. In vitro and ex vivo assays only.

  8. 08
    Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs

    He L, Feng D, et al. · Front Pharmacol 2022 · PubMed · DOI · Free full text

    Half-life under 30 minutes in rats and dogs after intravenous and intramuscular dosing, highest tissue levels in kidney, and breakdown to amino acids. Oral dosing was not studied.

  9. 09
    Advances in oral peptide therapeutics

    Drucker DJ · Nat Rev Drug Discov 2020 · DOI

    Review of the gut barriers, enzymes, mucus and epithelium, that keep most peptides and proteins from being absorbed intact by mouth, and of formulation strategies to overcome them. General review, not specific to BPC-157 or thymosin beta-4.

  10. 10
    The 2026 Prohibited List

    World Anti-Doping Agency · WADA, effective January 2026

    Lists BPC-157 as a non-approved substance (S0) and thymosin beta-4 and its derivatives, such as TB-500, as growth factor modulators (S2), prohibited at all times. Sport regulation only.

  11. 11
    FDA signals potentially evolving stance toward compounding of certain peptides

    Goodwin Procter LLP · Goodwin, May 2026

    Reports the FDA's April 15, 2026 removal of 12 peptides, including BPC-157 and the thymosin beta-4 fragment LKKTETQ ("TB-500"), from Category 2. Notes removal does not itself establish compounding eligibility. Legal commentary, not the FDA text.

  12. 12
    FDA panel backs 6 peptides for compounding

    AJMC staff · AJMC, July 2026

    The Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157, KPV and TB-500. Advisory votes are not binding and require FDA rulemaking.

Frequently asked questions

How is BPC-157 / TB-500 Capsules packaged?

BPC-157 / TB-500 Capsules is supplied in the product format and quantity shown for the selected variant. Please inspect the sealed package when it arrives and contact support promptly if the package or labeling appears damaged.

How is BPC-157 / TB-500 Capsules shipped?

Orders are shipped within the United States via USPS. Transit times are typically 3–7 business days, depending on destination and carrier conditions. Tracking information is provided when available.

How should BPC-157 / TB-500 Capsules be stored?

Storage requirements are product-specific. Keep BPC-157 / TB-500 Capsules in its original labeled container and follow the product documentation or manufacturer instructions supplied with the order. Contact support if the applicable storage guidance is not available.

What is the refund policy for BPC-157 / TB-500 Capsules?

Due to the nature of research materials, NextGenPeps orders are final and are not eligible for refunds, returns, or exchanges. Review the shipping and reship policies before ordering.

Is BPC-157 / TB-500 Capsules intended for human use?

No. NextGenPeps materials are supplied strictly for laboratory research and development use and are not intended for human or animal consumption, clinical use, diagnostic use, cosmetic use, or dietary use.

Customer reviews

4.7out of 5 · 3 reviews

Best caps out there

A great alternative to liquid BPC157 and TB500 without having to deal with reconstituting. The quality still remains at a high purity in capsule form.

Orion E.

On top of shipping

Every purchase I make from nextgenpeps arrives in days. Most of the other vendors I shopped at didnt even process my order in that time and it would take a full week just to get a tracking number.

Trevor M.

Stable Throughout Testing

I use all the different BPC products from here for preclinical research and have had no variation in purity or contaminants in any mixture.

Finn H.

Common research questions

What are BPC-157 and TB-500 capsules?

They are an oral research format holding two synthetic peptides, listed at 250 mcg of BPC-157 and 250 mcg of TB-500 per capsule. BPC-157 is a 15-residue peptide from a gastric juice protein, studied for blood vessel growth and tissue repair in rats. The TB-500 listed here is Ac-LKKTETQ, the seven-residue actin-binding fragment of thymosin beta-4, studied for cell migration. NextGenPeps sells them for in vitro and approved animal research only.

Does oral TB-500 work?

That has not been shown. No published study was found that gave full-length thymosin beta-4 or the LKKTETQ fragment to animals by mouth, so oral stability, absorption and activity are untested rather than disproven. The full-length protein is 43 residues, and peptides and proteins generally face digestive enzymes and the gut wall barrier that keep them from being absorbed intact. The fragment is much smaller, but no oral data were found for it either.

Does oral BPC-157 work in animal studies?

In rats, yes, in several models. BPC-157 is described as stable in gastric juice for more than 24 hours in vitro, and rats given it in drinking water healed surgically made fistulas; in one study, bladder-to-vagina fistulas stopped leaking within a week of therapy and bladder capacity reached five times that of controls by week four. Oral absorption has not been measured, and most of the oral work comes from a single research group.

Have BPC-157 and TB-500 been studied together?

Yes, in one 2026 rat study of repaired Achilles tendons, with both peptides injected daily for four weeks. Median load to failure was 26.9 N in controls, 37.2 N with BPC-157, 37.4 N with TB-500 and 34.5 N with both, and only TB-500 differed significantly from control. The combination did not outperform either peptide alone, and no study has given the pair by mouth.

What is the difference between these capsules and the BPC-157 / TB-500 vial blend?

The capsules are an oral format with a fixed 250 mcg of each peptide per capsule, while the vial blend is lyophilized powder reconstituted for injected-route models. The capsules are listed with the Ac-LKKTETQ fragment of thymosin beta-4, whereas the NextGenPeps TB-500 vial contains the full-length protein. The only combination study used injection, so its results apply to the injected route.

Are BPC-157 and TB-500 FDA approved?

No. In April 2026 the FDA removed BPC-157 and the LKKTETQ fragment it calls TB-500 from Category 2 of its compounding safety list, and in July 2026 its Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend them; the vote is not binding and rulemaking is still required. The World Anti-Doping Agency prohibits both at all times. NextGenPeps sells these capsules for research use only.

Frequently Researched with

Sermorelin

✓ 98.817% purity

Sermorelin

$78.00$62.00

GHK-Cu

✓ 99.73% purity

GHK-Cu

$74.00$59.00

You have an unfinished subscription checkout

Continue your saved checkout, or replace its item with . Your saved selection and existing subscriptions will stay unchanged.

Continue saved checkout
NextGenPeps

Reliable and innovative research with our top-grade research materials and novel research compounds tailored to lead the competitive research industry. Choose research quality. Choose NextGenPeps.

Customer Service: +1 (971) 300-1435

Get 10% Off Your First Order

Sign up now and receive a 10% discount code valid on your next purchase!

Nextgenpeps LLC

The statements made within this website have not been evaluated by the US Food and Drug Administration. The materials offered by this company are not intended to diagnose, treat, cure, or prevent any disease. All research materials on this site are for laboratory research and development use only, and are not intended for human use.

NextGenPeps is a chemical supplier. NextGenPeps is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. NextGenPeps is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.

Privacy PolicyTerms & ConditionsAffiliate Program

501 W Broadway Ste A, San Diego, CA 92101

© 2026 NextGenPeps. All rights reserved.

Visa
American Express
Mastercard
PayPal
Discover
Apple Pay